Nanōmix has obtained CE mark for its Covid-19 rapid point-of-care (POC) antigen panel, which is used with the company’s eLab analyser.

The eLab Covid-19 antigen test cartridge provides results in 15 minutes using an anterior nasal swab.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It enables qualitative detection of the SARS-CoV-2 virus nucleocapsid antigen from the swabs.

Nanōmix chief commercial officer John Hardesky said: “Receiving the CE mark for our Covid-19 rapid antigen test is a key milestone, which further validates our rapid and accurate POC testing technology.

“This assay complements our S1 Critical Infection Panel which provides valuable insight to clinicians as they diagnose and monitor severe, co-infections, including those of Covid-19 patients.”

A swab and sample collection tube included with the panel are used to collect nasal swab samples, which are then transferred to the single-use, microfluidic cartridge.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This cartridge is run on the Nanōmix eLab, which can print or send results electronically through Bluetooth.

The eLab system can also publish the test results output as a QR code, providing increased privacy.

Nanōmix president and CEO David Ludvigson said: “The Nanōmix eLab is a comprehensive diagnostic platform that has enormous potential in time-sensitive diagnostic applications.”

Federal funds from the Department of Health and Human Services, the Office of the Assistant Secretary for Preparedness and Response, and the Biomedical Advanced Research and Development Authority were used to fund the project in whole or in part.

Last February, Nanōmix submitted an Emergency Use Authorization request to the US Food and Drug Administration (FDA) for the portable, handheld eLab Covid-19 rapid antigen test.